It is possible that SGLT2 therapy may prove an effective means of reducing the risk of pancreatic cancer, thereby offering a potential avenue for the future reduction in pancreatic cancer incidence in patients with T2D. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.